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Summary
QUESTIONS UNDER STUDY/PRINCIPLES: Data re-
garding the prevalence and types of drug-related problems
(DRPs) among neurology inpatients is sparse. The object-
ive of this study was to characterise the types of DRPs
seen among neurology inpatients and furthermore to study
factors affecting the acceptance of clinical pharmacolo-
gists’ and pharmacists’ recommendations for improving
drug safety.
METHODS: 1,263 consecutive inpatient cases in a Swiss
university hospital neurology unit were assessed for the
presence of DRPs over 12 months. Treating neurologists’
acceptance of the resulting recommendations was also re-
corded. Primary outcome measures were types of DRP,
recommendations made by clinical pharmacologists and
number of recommendations accepted. Factors potentially
associated with acceptance were studied using univariate
and multivariate generalised estimating equation model-
ling.
RESULTS: Twenty-nine percent of cases demonstrated one
or more DRPs. DRPs were the cause of admission in 10
cases (0.8%). In total 494 DRPs were identified and 467 re-
commendations given, of which 62% were accepted. Fact-
ors associated with an increased likelihood of acceptance
were prescriptions involving regularly administered drugs
(odds ratio [OR] 2.57 95% confidence interval [CI]
1.73–3.80), adverse drug events (OR 2.5; 95% CI
1.29–5.06), known drug side-effect (OR 1.85; 95% CI
1.06–3.22), high-risk drug-drug interactions (OR 3.22;
95% CI 1.07–9.69) and interventions involving changing a
drug (OR 2.71; 95% CI 1.17–6.25).
CONCLUSION: Clinical pharmacologists and pharmacists
can play an important role in identifying DRPs among
neurology inpatients. Their recommendations for optim-
ising medication-safety are most likely to be accepted for
regular prescriptions, prescriptions associated with an ad-
verse drug event and high-risk drug combinations.
Key words: drug-related problems; neurology; clinical
pharmacology; clinical pharmacy; drug-safety; hospital;
acceptance
Introduction
Clinical pharmacologist- and clinical pharmacist-led ser-
vices for improving medication-safety in hospitals and in
the community have been shown to improve both patient-
and cost-related outcomes [1–3]. These services have been
well described for ambulatory and hospitalised internal
medicine, intensive care unit, family practice, surgery, psy-
chiatry and geriatric patients. The success of such services
depends on a number of factors including the accurate
identification of drug-related problems (DRPs), appropri-
ate suggestions about how these might be avoided and
the acceptance and implementation of these suggestions by
the treating medical practitioners. Clinical pharmacologists
and pharmacists must concentrate on all three of these as-
pects to ensure a benefit for patients.
The nature of DRPs among patients hospitalised with neur-
ological conditions has not been previously documented.
Furthermore, little is known about factors affecting the
acceptance of clinical pharmacologists’ and clinical phar-
macists’ recommendations by treating physicians. We have
previously shown that the use of electronic prescription
charts is one factor which aids both in the identification of
DRPs and the subsequent implementation of recommenda-
tions for improving drug safety among hospitalised patients
[4].
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We therefore conducted a study in neurology inpatients
for which electronic prescribing was exclusively employed
with an aim to characterise the types of DRPs and to study
additional factors which might affect the acceptance of re-
commendations for improving drug safety.
Patients and methods
Neurology inpatients on two separate wards in a large
Swiss university hospital were assessed for drug-related
problems (DRPs) on weekly consultant neurologist ward
rounds by two clinical pharmacologists and a pharmacist
between September 2009 and September 2010. All patients
were cared for using integrated electronic medical records
(with electronic prescribing). An additional feature of the
electronic prescription chart was the electronic drug inter-
actions check programme supplied by Pharmavista® [5].
This programme assessed potential drug-drug interactions
and graded these according to required intervention (based
on the Operational Classification of Drug Interactions by
Hansten et al. [6]) only when requested to do so by the pre-
scriber; it did not flag up potential problems automatically.
It was not possible to determine whether or how often the
interactions programme was used by the prescribing phys-
icians. Other than the voluntary drug interactions check,
no electronic clinical decision support (regarding dosing,
for example) was embodied in the electronic prescription
chart. Patients who remained in hospital for more than one
week or who were readmitted were assessed each time,
however, only new DRPs were commented upon. DRPs
which had previously been commented upon, but the sug-
gested intervention not implemented, were not commen-
ted upon again. This was to avoid over-alerting and also
had the advantage that the same problems were not coun-
ted twice (and therefore not over-represented) at the time of
data analysis. Unlike in our previous study where only reg-
ularly administered medication was commented upon [4],
this study assessed for DRPs in both “regular” and “as re-
quired” medication (given on a “pro re nata” or “PRN”
basis).
DRPs were defined according to the Pharmaceutical Care
Network Europe (PCNE) Classification for Drug-related
problems version 6.2 (revised 14.01.2010), which defines
a drug-related problem as “an event or circumstance in-
volving drug therapy that actually or potentially interferes
with desired health outcomes” [7]. DRPs were identified
and proposals for optimising drug safety were given to
the treating neurologists face-to-face on the ward round
and again later the same day in the form of electronic
notes (checked by the two senior clinical pharmacologists
in the team) in the patient records. Clinical pharmacologists
and pharmacists accessed internet based databases includ-
ing Swiss, German and American product information,
PubMed, the Pharmavista® tool and Micromedex® Health-
care Series [8].
All the detected DRPs, their causes and proposed inter-
ventions were then retrospectively classified according to
the PCNE classification system for reporting purposes. The
PCNE classification system has a number of limitations,
however. The large number of variables (n = 64 for prob-
lems, causes and interventions) makes statistical analyses
and comparisons difficult and it does not include the exact
nature of the intervention proposed by the clinical pharma-
cologist or pharmacist to ameliorate or minimise the DRP.
We therefore devised a simpler classification system based
on the PCNE for the purposes of determining factors which
were positively and negatively associated with the imple-
mentation of clinical pharmacologists’ proposals (table 1).
The outcome measures were the types of DRP, the recom-
mendations made by clinical pharmacologists and the num-
ber of these recommendations which were implemented by
the treating neurologists. Factors at the prescription-, DRP-
, causality- and intervention-levels potentially associated
with proposal acceptance were studied. Drug-drug interac-
tions were categorised according to Pharmavista®, where
“1” and “2” denote interactions with a high potential for
subsequent adverse outcome (so called “severe” interac-
tions) and “3”, “4” and “5” represent interactions of lesser
clinical importance [5]. Univariate analyses taking cluster-
ing by patient and ward into account were performed us-
ing generalised estimating equations (GEE) and odds ra-
tios generated. Each patient within each ward was treated
as a separate cluster and we included clinic and ward as ex-
planatory variables. Robust standard errors from the GEE
model were then extracted to compute a confidence inter-
val for the resulting odds ratio of interest. Of note, standard
errors from a GEE are also valid if the underlying correl-
ation structure is not correctly specified by our model as-
sumptions. Factors which were positively associated with
the primary outcome measure were then used to build a
multivariable logistic regression model to assess for the in-
dependent effects of these factors on increasing proposal
acceptance. A second model, using factors which were
negatively associated with the primary outcome measure
was constructed in a similar fashion. Both multivariable
models were adjusted for dependence on patient and ward
using GEE, and also adjusted for ward as an explanatory
variable in order to remove any potential source of bias
by ward. The latter was important as the patients on the
two wards were cared for by different neurologists and
their DRPs were consistently assessed by one clinical phar-
macologist on one ward and another clinical pharmacolo-
gist together with a pharmacist on the other ward. All ana-
lyses were performed using R (R Development Core Team,
2010) using the package “geepack” [9].
Results
Eighty-four ward rounds were attended and 1263 inpatient
cases assessed for the presence of drug-related problems
(fig. 1). In total 494 DRPs involving 704 individual drug
prescriptions in 367 inpatient cases (median age 68.7 years,
interquartile range 57.0–77.8 years) were identified. The
principal diagnoses at admission were confirmed or sus-
pected cerebral ischaemia or intracerebral bleeding (n =
145, 40%), Parkinson’s syndrome or extrapyramidal symp-
toms (n = 32), epilepsy (n = 29), primary or secondary
brain tumours (n = 20), multiple sclerosis (n = 9), infec-
tious nervous system disorders (n = 8), dementia (n = 7),
essential tremor (n = 6), gait disturbance (n = 5), chronic
headaches (n = 4) and chronic pain syndrome (n = 4). The
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remaining 98 patients had rarer diagnoses (less than 4 cases
per diagnosis).
Twenty-nine percent of the studied inpatient cases demon-
strated one or more DRPs. Interventions were proposed for
467 (95%) DRPs. No intervention was proposed for the re-
maining 27 DRPs, as these were either related to serious
adverse drug reactions for which the offending drug had
already been discontinued (n = 15) or related to the need
for additional information regarding individual pharmaco-
therapy (n = 12) (fig. 1).
There were 17 cases where an adverse drug reaction (ADR)
was judged to have occurred, representing 1.3% of the
cases studied. Fourteen of these were classified as non-al-
lergic and 3 allergic. The ADRs were intracerebral bleed-
ing (phenprocoumon n = 2, aspirin n = 2), sinus vein throm-
bosis (hormonal contraception n = 3) and one case each of
retroperitoneal bleeding (valproate and phenprocoumon),
acute renal failure (acyclovir), hepatotoxicity (amoxicillin/
clavulanic acid), lithium toxicity, stroke (celecoxib), herpes
simplex meningoencephalitis (etanercept), rash and liver
enzyme increase (lamotrigin), unclear weakness (H1N1
vaccination), haemolytic anaemia (human immuno-
globulin) and extrapyramidal syndrome (risperidone).
Drug-related problems were the cause of admission to the
neurology unit in 10 cases (representing 0.8% of all cases
studied).
The drugs most frequently implicated are listed in table
2 and included analgesics, antiplatelet agents, anticonvuls-
ants, lipid-lowering medication, proton-pump inhibitors
and night-sedation. The types of DRPs, their causes and
the resulting interventions carried out by the treating phys-
icians classified according to the Pharmaceutical Care Net-
work Europe (PCNE) Classification for Drug-related prob-
lems version 6.2 (revised 14.01.2010) [7] are shown in
Table 1: Acceptance of proposed interventions grouped according to the type of prescription, type of drug-related problem, underlying cause and proposed intervention.
Odds ratios are adjusted for potential dependence on ward and patient.
Entire
group
Accepted
(%)
Not
accepted
Odds ratio for acceptance
(95% confidence interval)
N 467 289 (62) 178
Type of drug prescription involved in the proposed intervention:
“Regular” prescriptions only 274 195 (71) 79 2.57 (1.73–3.80)
At least one “as required” agent 193 94 (49) 99 0.39 (0.26– 0.58)
Homeopathic or herbal remedies 6 6 (100) 0 Infinity
At least one anticoagulant or antiplatelet agent 50 38 (76) 12 1.98 (1.02– 3.84)
At least one antihypertensive agent 46 30 (65) 16 1.11 (0.61– 2.02)
At least one antidiabetic agent 11 7 (64) 4 1.29 (0.49–3.42)
Problems
Lack of efficacy 13 10 (77) 3 2.04 (0.60–6.92)
Potential lack of efficacy 66 45 (68) 21 1.32 (0.78–2.22)
Adverse drug event 59 47 (80) 12 2.56 (1.29–5.06)
Potential adverse drug event 319 184 (58) 135 0.58 (0.38–0.89)
Cost-issue 10 3 (30) 7 0.32 (0.09–1.19)
Causes
Known side-effect of drug(s) 76 56 (74) 20 1.85 (1.06–3.22)
Dose problem 69 39 (57) 30 0.77 (0.46–1.03)
Duplication of therapeutic class 8 4 (50) 4 0.69 (0.15–3.21)
Prescribing error 26 16 (62) 10 1.03 (0.45–2.37)
Error in documentation of allergies 33 14 (42) 19 0.45 (0.19–1.05)
Suboptimal choice of drug formulation 20 8 (40) 12 0.44 (0.18–1.07)
Interaction 182 119 (65) 63 1.23 (0.84–1.80)
– Proposed intervention involved alteration of a drug combination graded as level 1
or 2*
24 20 (83) 4 3.22 (1.07–9.69)
– Proposed intervention involved alteration of a drug combination graded as level 3,
4 or 5*
110 69 (63) 41 1.02 (0.65–1.6)
Indication (untreated indication or indication for a current treatment
requiring reassessment)
14 10 (71) 4 1.48 (0.45–4.83)
Contraindicated 38 22 (58) 16 0.88 (0.43–1.78)
Unknown cause 1 1 (100) 0 n/a
Proposed intervention
Change drug 40 32 (80) 8 2.71 (1.17–6.25)
Change drug formulation 21 8 (38) 13 0.40 (0.16–0.97)
Documentation of allergies 34 14 (41) 20 0.32 (0.15–0.72)
Dose reduction 119 72 (61) 47 0.97 (0.63–1.51)
Patient monitoring 71 48 (68) 23 1.23 (0.74–2.05)
Start drug 14 8 (57) 6 0.78 (0.28–2.23)
Stop drug 114 77 (68) 37 1.39 (0.86–2.14)
Therapeutic drug monitoring 17 10 (59) 7 0.85 (0.32–2.22)
Timing of drug administration 37 20 (54) 17 0.72 (0.35–1.45)
* Pharmavista did not report on 48 additional interactions which were detected by the clinical pharmacologists.
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table 3. The table also shows the distribution of these para-
meters according to implementation of proposed recom-
mendations. 289 (62%) of the 467 proposed interventions
were implemented by the treating neurologists. The com-
monest drug-drug interactions are given in table 4 along
with interaction severity grade and implementation. Drugs
for which all, none, greater than 50% or less than 50% of
recommendations were carried out are listed in table 5.
Factors potentially influencing the implementation of re-
commendations could be grouped into the following cat-
egories: (1.) type of medication-prescription, (2.) nature or
type of DRP, (3.) cause of DRP and (4.) recommended in-
tervention for minimising the DRP (table 1). Univariate
analysis taking potential clustering around patient and ward
into account showed prescriptions involving only regularly
administered drugs, prescriptions involving at least one an-
ticoagulant or one antiplatelet agent, DRPs which were ad-
verse drug events, DRPs which caused manifestation of
a known drug side-effect, DRPs caused by a grade 1 or
2 drug-drug interaction and interventions involving chan-
ging a drug were all associated with an increased likelihood
of implementing the clinical pharmacologists’ and phar-
macists’ recommendations (table 1). Similarly, factors as-
Figure 1
Study flow-chart.
sociated with a reduced chance of implementation were
prescriptions involving a drug given on an “as required”
basis, a DRP which had the potential to cause an adverse
drug event, recommendations to change the administered
drug formulation and recommendations to document drug
allergies and intolerances in the appropriate place (table 1
– see Methods for definition of interaction grades).
While 71% of recommendations involving “regular” med-
ication were implemented, only 49% of recommendations
involving at least one “as required” medication were accep-
ted. Multivariate analysis showed the type of prescription
(whether for “regular” or “as required” medication) was the
sole independent determinant of acceptance. After adjust-
ment for the factors positively associated with implementa-
tion shown in table 1 and adjustment for ward, the odds ra-
tio for “regular” medication was 2.31 (95% CI 1.51–3.53).
After adjustment for the factors which were negatively as-
sociated with implementation (table 1) and adjustment for
ward, the odds ratio for “as required” medication was 0.47
(95% CI 0.3–0.73) (table 6). The entire multivariable mod-
el and the associated adjusted odds-ratios and p-values are
shown in table 6.
There were 38 cases where a contraindicated drug-therapy
was prescribed. In twenty-two cases prescriptions were
changed on the basis of our recommendations and included
all recommendations regarding contraindicated drug-drug
combinations. Recommendations which were not imple-
mented were where the product information cited underly-
ing conditions or diseases as precluding drug use such as
tramadol or metoclopramide in epilepsy (n = 5), ACE in-
hibitor, nonsteroidal anti-inflammatory drugs, eplerenone
or metformin in renal impairment (n = 6), anticoagulation
in the setting of thrombocytopenia or recent history of
bleeding (n = 2), metamizole in the setting of agranulocyt-
osis (n = 1), domperidone in the setting of QTc prolonga-
tion (n = 1) and reserpine in the setting of depression (n =
1).
Although not systematically examined for the purposes of
this study, there were examples where implementation of
the proposed intervention led to a clear benefit for the pa-
tient during the period of hospitalisation. This included a
case where symptomatic hypoglycaemia developed after
the introduction of a fibrate to on-going glibenclamide
therapy. On conversion of the fibrate to a statin as recom-
mended, no further hypoglycaemic events occurred. In a
further case an elevation in serum transaminases norm-
Table 2: Top 10 drugs featuring in the 494 drug-related problems (in total 704 drug prescriptions were involved in the drug-related problems).
Drug Class Number Percentage of prescriptions
Zolpidem Sedative 62 8.8%
Paracetamol Antipyretic/analgesic 48 6.8%
Aspirin Antiplatelet agent 28 4%
Phenytoin Anticonvulsant 23 3.3%
Atorvastatin Lipid lowering agent 22 3.1%
Diclofenac Antipyretic/analgesic 21 3%
Clopidogrel Antiplatelet agent 20 2.9%
Esomeprazole Proton pump inhibitor 18 2.6%
Ibuprofen Antipyretic/analgesic 17 2.4%
Carbamazepine Anticonvulsant 16 2.3%
Domperidone* Antiemetic 16 2.3%
*Dopamine antagonist, not licensed in USA
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Table 3: Classification of the 494 drug-related problems according to Pharmaceutical Care Network Europe Classification for Drug-Related Problems Version 6.2.
Characteristic Entire group No proposal
made
Proposal
accepted
Proposal not
accepted
Number of drug-related problems 494
Number of proposals 467 27 289 178
The Problem
P1: Treatment effectiveness:
There is a (potential) problem with the (lack of) effect of the pharmacotherapy.
P1.1 No effect of drug treatment/therapy failure
P1.2 Effect of drug treatment not optimal
P1.3 Wrong effect of drug treatment
P1.4 Untreated indication
5 (all manifest)
78 (2 manifest)
0
8
2
10
0
0
3
47
0
5
0
21
0
3
P2: Adverse reactions: Patient suffers, or will possibly suffer, from an adverse drug event.
P2.1 Non-allergic
P2.2 Allergic
P2.3 Toxic
27 (14 manifest)
41 (3 manifest)
321
8
2
5
14
16
199
5
23
117
P3: Treatment costs:
P3.1 Drug treatment more costly than necessary
P3.2 Unnecessary drug treatment
10
4
0
0
3
2
7
2
The Cause
C1: Drug selection
C1.1 Inappropriate drug (including contra-indicated)
C1.3 Inappropriate combination of drugs
C1.4 Inappropriate duplication of therapeutic group or active ingredients
C1.5 Indication for drug-treatment not noticed
C1.7 More cost-effective drug available
C1.8 Synergistic/preventive drug required and not given
C1.9 New indication for drug treatment presented
61
50
30
5
10
8
1
0
0
0
0
0
0
0
38
34
19
3
3
6
0
23
16
11
2
7
2
1
C2: Drug form
C2.1 Inappropriate drug form 11 0 5 6
C3: Dose selection
C3.1 Drug dose too low
C3.2 Drug dose too high
C3.3 Dosage regimen not frequent enough
C3.4 Dosage regimen too frequent
C3.5 No therapeutic drug monitoring
C3.6 Pharmacokinetic problem requiring dose adjustment
1
22
1
5
15
120
1
0
0
0
0
9
0
17
0
2
8
66
0
5
1
3
7
45
C5: Drug use process
C5.1 Inappropriate timing of administration and/or dosing intervals 28 0 18 10
C8: Other
C8.1 Other cause*
C8.2 No obvious cause
126 17 70 39
The Intervention
I0.0: No intervention 27 27 – –
I1. At prescriber level
I1.1 Prescriber informed only
I1.2 Prescriber asked for information
I1.3 Intervention proposed, approved by Prescriber
I1.4 Intervention proposed, not approved by Prescriber
I1.5 Intervention proposed, outcome unknown
12
0
289
178
0
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
I3: At drug level
I3.1 Drug changed
I3.2 Dose changed
I3.3 Formulation changed
I3.4 Instructions for use changed
I3.5 Drug stopped
I3.6 New drug started
34
70
8
19
78
8
–
–
–
–
–
–
34
70
8
19
78
8
–
–
–
–
–
–
I4: Other intervention or activity
I4.1 Other intervention**
I4.2 Side effect reported to authorities
72
15
–
–
72 –
–
* Predictable adverse reactions were classified under this heading
** Other interventions consisted of therapeutic drug monitoring, documentation of allergies and patient monitoring.
There were no DRPs in the following categories: The Problems: P4 Other problems: P4.1 Patient dissatisfied with therapy, P4.2 Unclear problem; The Causes C1 Drug
selection: C1.2 No indication for drug, C1.6 Too many drugs prescribed for indication, C3.7 Deterioration/improvement of disease state requiring dose adjustment, C4:
Treatment duration: C4.1 Duration of treatment too short, C4.2 Duration of treatment too long; C5: Drug use process: C5.2 Drug underused/under-administered
(deliberately), C5.3 Drug overused/over-administered (deliberately), C5.4 Drug not taken/administered at all, C5.5 Wrong drug taken/administered, C5.6 Drug abused
(unregulated overuse), C5.7 Patient unable to use drug/form as directed; C6. Logistics: C6.1 Prescribed drug not available, C6.2 Prescribing error (necessary information
missing), C6.3 Dispensing error (wrong dose or drug dispensed); C7: The Patient: C7.1 Patient forgets to use/take drug, C7.2 Patient uses unnecessary drug, C7.3 Patient
takes food that interacts, C7.4 Patient stored drug inappropriately; C8 Other: C8.2 No obvious cause; The Interventions I2: At patient/carer level I2.1 Patient (medication)
counselling, I2.2 Written information provided only, I2.3 Patient referred to prescriber, I2.4 Spoken to family member/caregiver.
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alised after the recommended atorvastatin dose reduction
was carried out.
Discussion
Drug-related problems
This study describes the role of clinical pharmacologists
and clinical pharmacists in the detection and avoidance of
DRPs among neurology inpatients. Twenty-nine percent of
cases demonstrated at least one DRP. This compares more
favourably with the 80% seen in a large study of 827 pa-
tients hospitalised with internal medical or rheumatologic-
al conditions [10] and a study of geriatric inpatients which
found a DRP prevalence of 78% [11]. Both these latter
studies defined DRPs according to the PCNE system as
in the current study, however, DRPs were solely detected
through chart reviews and not attendance on ward rounds.
It is likely that attendance on ward rounds enables a more
accurate identification of clinically relevant DRPs, which
could be an explanation for the lower DRP prevalence seen
in our study. In attending ward rounds, clinical pharmaco-
logists and pharmacists are able to gain an insight into the
patient case as a whole and can thereby provide patient-
specific recommendations and avoid false positive DRP
detection.
It is well known that the vast majority of DRPs are avoid-
able, as we also found in this study. Root causes of the
DRPs in this patient group were not specifically analysed
but were likely to have been due in part to continued pre-
scription of problematic drug regimes initiated prior to hos-
pital admission, switching to “hospital list” medication and
thereby causing a new drug-drug interaction and use of
standardised prescriptions for “as required” medication (a
function facilitated by electronic prescribing). This latter
aspect accounts for the high number of DRPs arising from
“as required” prescriptions for zolpidem and paracetamol
for example, in which dose adjustment for age or the pres-
ence of concomitant enzyme-inducing agents are not auto-
matically carried out.
The adverse drug reaction frequency of 1.3% was smaller
than in our previous study of medical inpatients admitted to
the same hospital (3.7%) [4] but in keeping with a previous
study in internal medicine and surgery inpatients (1.7%)
[12]. A recent review of DRPs in hospitals has collated
data from a number of studies reporting the frequency of
ADRs detected and found a range of 1.3 to 60.7% [13].
The data presented here clearly lie at the lower limit of this
range and may reflect the fact that the patients were be-
ing cared for in a specialist unit. Adverse drug reactions
as the cause for admission (0.8%) were also fewer than in
other observational studies conducted in Switzerland (4.1%
of admissions to internal medicine wards in a study con-
ducted between 1996 and 2000) [14]. Another large study
conducted in the UK found 5.2% of all hospital admissions
to be directly related to an ADR with the most common
cause for an ADR-related admission being gastrointestinal
bleeding [15]. The lower prevalence of ADRs as the cause
of admission in our study most likely reflects the fact that
adverse drug events less commonly present as an isolated
neurological problem requiring specialist neurologist care
(sinus vein thrombosis in association with hormonal con-
traception being a notable exception).
DRPs arose mainly in medication not specifically licensed
for the treatment of neurological conditions (table 2).
Seventy-nine percent of the drugs where all recommend-
ations were implemented (15 out of 19) were not ones
primarily prescribed for the treatment of a neurological
condition (table 5). These observations not only provide
evidence for good pharmaceutical practice in the speciality
but also provide evidence that clinical pharmacologists and
pharmacists can contribute significantly to non-speciality
aspects of patient pharmacotherapeutics.
Acceptance
The acceptance of recommendations for improving
medication-safety in this study of neurology inpatients was
62% which is in line with our previous study of hospital-
ised medical inpatients cared for using electronic prescrip-
tion charts [4]. For drugs administered regularly, the ac-
Table 4: Ten commonest drug-drug interactions and implementation of the resulting suggestions. The total number of detected drug-drug interactions for which
interventions were proposed was 182.
Interacting drugs Potential consequence Severity grade* Number of cases
(% total
interactions)
Number of
proposals
accepted
Clopidogrel – esomeprazole Reduction in clopidogrel efficacy 2 15 (8.2) 14
Aspirin – ibuprofen Reduction in aspirin efficacy 3 13 (7.1) 8
Phenytoin – paracetamol Increased paracetamol-induced hepatotoxicity 4 12 (6.6) 7
Zolpidem – lorazepam Over-sedation ** 9 (4.9) 5
Levothyroxine – cations (calcium, magnesium) Reduction in levothyroxine absorption 3 8 (4.4) 4
Carbamazepine – paracetamol Increased paracetamol-induced hepatotoxicity 4 7 (3.8) 3
Domperidone – atypical neuroleptics Increased risk of Torsades de Pointes 3 7 (3.8) 4
Amiodarone – atorvastatin Increased atorvastatin toxicity (rhabdomyolysis) 3 5 (2.7) 4
Ciprofloxacin – olanzapine Increased risk of Torsades de Pointes 5 3 (1.6) 2
Phenobarbital – paracetamol Increased paracetamol-induced hepatotoxicity 4 2 (1.1) 0
Valproate – topiramate Risk of hyperammonaemia 3 2 (1.1) 2
Metformin – radioopaque contrast medium Risk of acute renal failure and lactic acidosis ** 2 (1.1) 2
* Grade 1 = Contraindicated drug combination; grade 2 = relatively contraindicated drug combination; grade 3 = this drug combination requires dose adjustment and/or
monitoring for adverse drug reactions; grade 4 = in patients with risk factors, this drug combination requires dose adjustment and/or monitoring for adverse drug reactions;
grade 5 = this drug combination requires monitoring for adverse drug reactions.
** Interaction not rated by Pharmavista®.
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ceptance was 71%, while for drugs administered on an “as
required” basis the acceptance was significantly lower at
49%; this association remained after adjustment for other
univariate factors, most likely reflecting the study power
for this variable conferred by the large numbers (247 reg-
ular prescriptions and 193 “as required”). Nonetheless, ex-
amination of factors which were associated with increased
acceptance and those associated with decreased acceptance
provide interesting information. Recommendations regard-
ing a potential adverse event, for example, were less likely
to be implemented and could signal over-alerting. High-
risk drug-drug interactions, on the other hand, were more
likely to be implemented and are a good example of where
a clinical pharmacologist can bring specialist knowledge to
patient care.
It is known from studies of electronic clinical decision sup-
port systems that over-alerting is associated with overrid-
ing of recommendations for improving drug safety, partic-
ularly as the alerts are often not clinically relevant [16–18].
Indeed as many as 91% of electronically generated alerts
pertaining to drug-drug interactions may be ignored [16].
The danger in such cases is that important, clinically rel-
evant drug-related problems are missed and the appropriate
action to stop or prevent adverse events is not taken when it
should be. By providing a physician- and/or pharmacist-led
service for flagging-up relevant drug-related problems and
providing suggestions for avoiding these, situations such
as the latter should hopefully be avoided. Indeed, while
electronic decision support appears to have a very low
implementation, face-to-face clinical pharmacist interven-
Table 5: Acceptance of recommendation according to the drugs involved in the drug-related problems. Only drugs which featured in more than 1 drug-related problem are
shown.
All recommendations accepted At least 50% of recommendations
accepted
Less than 50% of recommendations
accepted
No recommendations accepted
Aciclovir Acetaminophen Citalopram Amitriptylline
Aldactone Amiodarone Dalteparin Azathioprine
Alendronate Amoxicillin/clavulanate Domperidone Betainterferon
Amiloride Aspirin Hydrochlorothiazide Finasteride
Amphotericin Atorvastatin Levothyroxine Paraffin fecal softener
Escitalopram Calcium supplements Phenobarbital
Folic acid Captopril Primidone
Gingko biloba Carbamazepine Trimipramine
Indapamide Celecoxib
Iodine-containing radioopaque contrast
medium
Ciprofloxacin
Levetiracetam Clopidogrel
Oxcarbazepine Clozapine
Phosphate-based bowel preparation Diclofenac
Potassium supplements Enalapril
Quetiapine Enoxaparin
Saccharomyces boulardii Esomeprazole
Simvastatin Ibuprofen
Topiramate Indomethacin
Valsartan Lisinopril
Lithium
Lorazepam
Magnesium supplements
Metamizole
Metformin
Metoclopramide
Mirtazapine
Morphine
Olanzapine
Perindopril
Phenprocoumon
Phenytoin
Pipamperone
Ramipril
Rasagiline
Tamsulosin
Tizanidine
Tramadol
Trazodone
Trimethoprim/sulfamethoxazole
Valproate
Venlafaxine
Zolpidem
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tions have been associated with rates as high as 83% for
general medical hospital inpatients [19] and 96% for outpa-
tients attending a specialist hypertension clinic [20]. These
studies were however smaller than the current study and it
is not clear whether “regular” and “as required” medication
or solely “regular” medication was commented upon. The
acceptance rate in specialist neurology units has not been
formally assessed and reported before.
Clinical pharmacologists’ and clinical pharmacists’ recom-
mendations for improving medication-safety ought to focus
on the likelihood of outcomes in order to alert clinicians ap-
propriately about potential adverse drug events. For drugs
which are prescribed to be administered on an “as required”
basis, the likelihood of outcomes is by definition low, as the
exposure is low compared to drugs which are given daily.
In order to improve the implementation of recommenda-
tions for improving medication-safety, the underlying pro-
cesses need to be considered. De Almeida Neto and Chen
have reviewed the likely role of the treating-physicians’
psychological “reactance” to recommendations by clinical
pharmacists [21]. Reactance is defined as “a reaction to a
recommendation to take a certain course of action which is
affected by a motivational state compelling a response in
which freedom of choice is maintained” [21]. The greater
the number of seemingly non-beneficial recommendations,
the greater the physicians’ reactance to them is likely to be.
One method of reducing reactance would be to restrict re-
commendations to those with the highest clinical relevance
and most likely benefit. A further method, as suggested by
de Almeida Neto is to provide prescribing physicians with
choices, so that their sense of freedom of choice is main-
tained [21].
Limitations
Being carried out over 12 consecutive months could mean
that a learning effect of the neurologists cannot be ruled
out. However, we do not think this played a significant
role as the junior physicians, who have the main prescrib-
ing role, changed positions in 3 to 6 month cycles and
their supervising seniors changed positions in 6 to 9 month
cycles. A further limitation is the lack of systematic long-
term follow-up data regarding the effect of clinical
pharmacologist-initiated interventions and patient out-
come. Whether the study findings are likely to be gener-
alisable to other patient settings, other clinical pharmaco-
logy and clinical pharmacist services and other prescribers
is not apparent. There was also a power-dominance of the
“regular” and “as-required” prescriptions in the multivari-
able analysis in this study. Further, larger studies in dif-
ferent settings focussing particularly on regular prescrip-
tions are warranted in order to more accurately determine
factors affecting prescriber decision-making to accept or
reject clinical pharmacologists’ and clinical pharmacists’
recommendations.
Conclusions
Clinical pharmacologists and pharmacists can play an im-
portant role in identifying DRPs and optimising
medication-safety among neurology inpatients. Their re-
commendations for optimising medication-safety are most
likely to be accepted for regular prescriptions, prescriptions
associated with an adverse event and high-risk drug com-
binations.
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Figures (large format)
Figure 1
Study flow-chart.
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